Standout Papers

Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b–3 ... 2023 2026 2024121
  1. Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b–3 trial (2023)
    Brett King, Xingqi Zhang et al. The Lancet

Immediate Impact

13 from Science/Nature 84 standout
Sub-graph 1 of 21

Citing Papers

Rational Design of Biomaterials to Potentiate Cancer Thermal Therapy
2023 Standout
Metal-Based Photosensitizers as Inducers of Regulated Cell Death Mechanisms
2023 Standout
3 intermediate papers

Works of Amy Freyman being referenced

Neratinib, an Irreversible Pan-ErbB Receptor Tyrosine Kinase Inhibitor: Results of a Phase II Trial in Patients With Advanced Non–Small-Cell Lung Cancer
2010

Author Peers

Author Last Decade Papers Cites
Amy Freyman 410 319 258 12 633
R. Caputo 413 193 316 17 698
R R Hall 310 134 225 9 647
Bill Angus 380 73 281 21 710
Irene De Santo 381 328 163 13 665
Kelly L. Mueller 255 130 300 14 672
L. G. Bobrow 416 60 308 13 704
Peter C. Haughney 114 346 316 19 703
Parula Mehta 311 169 232 11 647
Lena Haney 278 199 145 12 516
Sundhar Ramalingam 274 187 286 25 650

All Works

Loading papers...

Rankless by CCL
2026